152 related articles for article (PubMed ID: 26256870)
1. [Genetic and epigenetic abnormalities in myeloproliferative neoplasms].
Kameda T; Shide K; Shimoda K
Rinsho Ketsueki; 2015 Jun; 56(6):614-22. PubMed ID: 26256870
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Hidaka T; Kubuki Y; Sashida G; Aoyama K; Yoshimitsu M; Abe H; Miike T; Iwakiri H; Tahara Y; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Genom Data; 2015 Jun; 4():102-8. PubMed ID: 26484191
[TBL] [Abstract][Full Text] [Related]
3. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
4. [Recent advances in molecular pathogenesis of myeloproliferative neoplasms].
Ikeda K
Rinsho Ketsueki; 2016 Feb; 57(2):156-64. PubMed ID: 26935633
[TBL] [Abstract][Full Text] [Related]
5. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Taniguchi Y; Hidaka T; Kubuki Y; Shimoda H; Marutsuka K; Sashida G; Aoyama K; Yoshimitsu M; Harada T; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Blood; 2015 Jan; 125(2):304-15. PubMed ID: 25395421
[TBL] [Abstract][Full Text] [Related]
6. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
7. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
8. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
9. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
Prick J; de Haan G; Green AR; Kent DG
Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
[TBL] [Abstract][Full Text] [Related]
10. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
[TBL] [Abstract][Full Text] [Related]
11. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in Myeloproliferative Neoplasms.
McPherson S; McMullin MF; Mills K
J Cell Mol Med; 2017 Sep; 21(9):1660-1667. PubMed ID: 28677265
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Chen E; Schneider RK; Breyfogle LJ; Rosen EA; Poveromo L; Elf S; Ko A; Brumme K; Levine R; Ebert BL; Mullally A
Blood; 2015 Jan; 125(2):327-35. PubMed ID: 25281607
[TBL] [Abstract][Full Text] [Related]
14. [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].
Kubuki Y; Hidaka T; Shimoda K
Rinsho Ketsueki; 2015 Oct; 56(10):1996-2004. PubMed ID: 26458438
[TBL] [Abstract][Full Text] [Related]
15. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract][Full Text] [Related]
16. TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran.
Abedi E; Ramzi M; Karimi M; Yaghobi R; Mohammadi H; Bayat E; Moghadam M; Farokhian F; Dehghani M; Golafshan HA; Haghpanah S
Int J Organ Transplant Med; 2021; 12(3):12-20. PubMed ID: 35509721
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
[TBL] [Abstract][Full Text] [Related]
19. Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.
Kjær L
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731609
[TBL] [Abstract][Full Text] [Related]
20. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.
Klein C; Zwick A; Kissel S; Forster CU; Pfeifer D; Follo M; Illert AL; Decker S; Benkler T; Pahl H; Oostendorp RA; Aumann K; Duyster J; Dierks C
J Exp Med; 2016 Feb; 213(2):273-90. PubMed ID: 26834157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
